IGF1 and Parkinson disease: An elevation of IGF-1, a peptide involved in growth, maturation and survival of neurons, has been shown in an early phase of Parkinson’s disease in humans, gradually decreasing in the middle/late stages of the disease (29); this could be regarded as a compensatory mechanism aimed at protecting dopaminergic neurons from initial degeneration.